Citranvi Biosciences

Citranvi® Biosciences is a pre-clinical stage North Carolina company led by a seasoned leadership team with significant experience in technologies for clinical development and commercialization of vaccines. Citranvi® has obtained a worldwide exclusive license from the Dept of Defence (DoD) to develop vaccines utilizing it’s herpesvirus protein multimeric technology platform. Citranvi will first develop two multi-antigen vaccines against infectious diseases caused by (1) cytomegalovirus (CMV) and (2) Epstein-Barr virus (EBV) for which at present there are no licensed vaccines. The goal for Citranvi® is to advance the two vaccine candidates (CMV and EBV) into Phase 1 and Phase 2 clinical trials to evaluate safety and immunogenicity to support Phase 3 efficacy and safety trials needed for commercialization. Citranvi seeks investment capital to move the CMV and EBV vaccines into Phase 1 and 2 studies utilizing clinical trial vaccine materials and commercialization via partnerships.